CTRI/2010/091/000122已完成3 期
A phase III, multicenter, open label, single treatment clinical study to evaluate the safety and efficacy of FDC of Telmisartan 80/40/20mg + Amlodipine 10/5/2.5mg + Hydrochlorthiazide 25/12.5/12.5mg tablet in mild, moderate and severe hypertensive patients.
Vapi Care Pharma Pvt Ltd0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Written informed consent from the patient.
- •-Male and female patients with age above 18 years inclusive.
- •-Diagnosis of mild, moderate & severe hypertensive patients with or without concomitant diabetes.
- •-Patients who will be uncontrolled on monotherapy with or without diabetes mellitus will be included in this study.
排除标准
- •-Patients with any condition which in the opinion of the investigator makes the patient unsuitable for inclusion.
- •-Known or suspected secondary hypertension.
- •-Patient with history of asthma or angina.
- •-Patient is a female who is pregnant or willing to get pregnant, not ready to use contraceptive measures during the trial period or breast feeding.
- •-Known hypersensitivity to Telmisartan, Amlodipine and Hydrochlorthiazide.
- •-Patient who is consuming/ has received drugs, which have interaction with Telmisartan, Amlodipine and Hydrochlorthiazide, during last 14 days.
- •-Participation in any other clinical trial during last 30 days.
研究者
相似试验
已完成
3 期
A clinical trial to evaluate the efficacy and safety of Glutathione in patients with alcoholic and non-alcoholic fatty liver disease.CTRI/2010/091/000087yka Labs Limited
招募中
1 期
Asciminib treatment optimization in = 3rd line CML-CPChronic Myelogenous Leukemia in chronic phase (CML-CP)MedDRA version: 21.0Level: LLTClassification code: 10009012Term: Chronic myelogenous leukemia Class: 10029104CTIS2024-511381-36-00ovartis Pharma AG205
进行中（未招募）
1 期
A Study of the Efficacy and Safety of Drug BAX 802 in Subjects with Congenital Hemophilia A with Factor VIII Inhibitors Undergoing Surgical or Other Invasive ProceduresCongenital Haemophilia A with Factor VIII InhibitorsMedDRA version: 20.0Level: LLTClassification code 10053751Term: Hemophilia A with anti factor VIIISystem Organ Class: 100000004850EUCTR2015-005521-39-BGBaxalta Innovations GmbH8
已完成
3 期
A Phase 3, Multicenter, Single-arm, Open-label Study of the Efficacy and Safety of B-Domain Deleted Recombinant Porcine Factor VIII (BAX 802) in Subjects with Congenital Hemophilia A with Factor VIII Inhibitors Undergoing Surgical or Other Invasive Proceduresbleeding disorder1003553410005330Hemophilia ANL-OMON47364Baxter1
进行中（未招募）
1 期
A Study of the Efficacy and Safety of Drug BAX 802 in Subjects with Congenital Hemophilia A with Factor VIII Inhibitors Undergoing Surgical or Other Invasive ProceduresCongenital Haemophilia A with Factor VIII InhibitorsMedDRA version: 20.0Level: LLTClassification code 10053751Term: Hemophilia A with anti factor VIIISystem Organ Class: 100000004850EUCTR2015-005521-39-GBBaxalta Innovations GmbH12